The induction of both CD4+ and CD8+ T cell responses will be of central importance for vaccine protection against HIV-1. However, a number of major questions must be answered before a vaccine can be developed that optimizes these immune responses. While we know that an optimal vaccine-induced antibody response will require CD4+ T cell help, the nature of the help that will potentiate the highest titer and most durable antibody response remains unclear. Although CD8+ T cells have been shown to contribute to containment of HIV-1 replication, the effectiveness of this anti-viral response is limited by the extreme sequence variability of circulating HIV-1 strains and the propensity of the virus to mutate away from recognition by these effector cells. Truly effective CD8+ T cell containment of HIV-1 replication can only occur if T cell responses are generated through vaccination that can pre-empt the ability of the virus to escape from cellular immune recognition. The studies described in this focus address these central issues in HIV-1 vaccine development.
Specific Aims are as follows.
Aim 1. Evaluate different priming vectors for their ability to stimulate CD4+ Th2 cells and T follicular helper (Tfh) cells in macaques.
Aim 2. Characterize CD4+ Th2 cell and Tfh cell responses elicited by HIV-1 vaccines in humans Aim 3. Determine impact of naive repertoires on post-vaccination response of HIV-1 Env-specific CD4+T cells in humans.
Aim 4. Compare mosaic and conserved region vaccines for their induction of CD8+ T cell responses.
Aim 5. Apply new understanding of immunodominance to improve vaccine-elicited CD8+ T cell responses. The information gained in addressing these aims will lead directly to the design of the next generation of vaccines that will stimulate more protective CD4+ T cell and CD8+ T cell responses.
An effective HIV vaccine will have to stimulate long lasting antibody response and cellular (T cell) immune responses. Two types of T cells are important, CD4+ T cells that help B cells to generated effective antibody and CD8+ T cells that act directly on virus infected cells. This focus will find new ways to generate both.
|Chen, Jia; Frey, Gary; Peng, Hanqin et al. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 88:1249-58|
|Hraber, Peter; Seaman, Michael S; Bailer, Robert T et al. (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-9|
|Pollara, Justin; Bonsignori, Mattia; Moody, M Anthony et al. (2014) HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88:7715-26|
|Verkoczy, Laurent; Diaz, Marilyn (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9:224-34|
|Hwang, Kwan-Ki; Trama, Ashley M; Kozink, Daniel M et al. (2014) IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. PLoS One 9:e90725|
|Haynes, Barton F; Moody, M Anthony; Alam, Munir et al. (2014) Progress in HIV-1 vaccine development. J Allergy Clin Immunol 134:3-10; quiz 11|
|Holl, T Matt; Yang, Guang; Kuraoka, Masayuki et al. (2014) Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-79|
|Roederer, Mario; Keele, Brandon F; Schmidt, Stephen D et al. (2014) Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-8|
|Dennison, S Moses; Anasti, Kara M; Jaeger, Frederick H et al. (2014) Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. J Virol 88:9406-17|
|Fera, Daniela; Schmidt, Aaron G; Haynes, Barton F et al. (2014) Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A 111:10275-80|
Showing the most recent 10 out of 48 publications